Harbor SMID Cap Value ETF Q2 2026 Contributors And Detractors

In Q2 2026, the Harbor SMID Cap Value ETF returned 22.76%, outperforming its benchmark, the Russell 2500 Value Index, which returned 18.50%. Contributing to performance was Albany International, whose shares gained 43% during the quarter following better-than-expected operating results and continued strength in its aerospace and defense businesses. Another contributor to performance was BorgWarner, whose shares gained 23% during the quarter following better-than-expected first quarter results and growing investor optimism around the company's long-term growth opportunities.

Seeking Alpha • Sep 19, 2026

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.

Zacks Investment Research • Sep 16, 2026

Harbor Small Cap Value Fund Q2 2026 Contributors And Detractors

The Harbor Small Cap Value Fund returned 21.09%, outperforming the Russell 2000 Value Index, which returned 17.19%, net of fees, during Q2 2026. Contributing to performance was Albany International Corp., a manufacturer of specialized engineered materials serving the paper production and aerospace industries. We made no purchases or sales in the second quarter of 2026.

Seeking Alpha • Sep 8, 2026

Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Aug 28, 2026

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.

Business Wire • Aug 26, 2026

CONMED Corporation: Organic Growth Is Masked By Divestitures

Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.

Seeking Alpha • Aug 18, 2026

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

Zacks Investment Research • Aug 17, 2026

Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.

Zacks Investment Research • Aug 17, 2026

Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

Zacks Investment Research • Aug 17, 2026

CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

Zacks Investment Research • Aug 17, 2026